Kiniksa Q2 ARCALYST Revenue Surges 55% to $243.6M; Full-Year Guidance Raised to $980–$995M

summarizeSummary

Kiniksa reported Q2 2026 ARCALYST revenue of $243.6M (+55% YoY), raised full-year guidance to $980–$995M, and advanced its pipeline with the pivotal KPL-387 trial now enrolling.

check_boxKey Events · Earnings and Guidance · KNSA

• ARCALYST Revenue Surges 55%

  Q2 2026 net product revenue reached $243.6 million, up from $156.8 million in Q2 2025, driven by an increase in patients on therapy.

• Full-Year Guidance Raised

  Management increased 2026 ARCALYST revenue guidance to $980–$995 million, reflecting strong demand and commercial execution.

• KPL-387 Pivotal Trial Enrolling

  The Phase 3 PASTORALE trial for KPL-387 in recurrent pericarditis began enrolling patients, supported by positive Phase 2 data; commercialization targeted for 2028–2029.

• Manufacturing Supply De-Risked

  FDA approved Samsung Biologics as a replacement CDMO for ARCALYST drug substance, adding a second source and reducing supply chain risk.

auto_awesomeAnalysis · KNSA · Life Sciences

Kiniksa delivered a standout quarter driven by ARCALYST, its IL-1 trap for recurrent pericarditis. Net product revenue jumped 55% year-over-year to $243.6 million, prompting management to raise full-year guidance to $980–$995 million. The pivotal Phase 3 trial for next-generation KPL-387 is now enrolling, and the FDA approved Samsung as a second manufacturing source, de-risking supply. With $525.9 million in cash and investments and a profitable quarter, the company is funding its pipeline from operations — a rare position in biotech. The stock is trading near its 52-week high, reflecting the market's positive reception to the growth trajectory.